Claims for Patent: 10,316,091

Summary for Patent: 10,316,091

Title:	Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
Abstract:	The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Inventor(s):	John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
Assignee:	Bristol Myers Squibb Co
Application Number:	US16/024,333

Details for Patent 10,316,091

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	September 25, 2009	10,316,091	2038-06-29
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	December 30, 2009	10,316,091	2038-06-29
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	December 23, 2013	10,316,091	2038-06-29

International Patent Family for US Patent 10,316,091

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013173223
United States of America	9856320
United States of America	9212224